People thumbnail


Recent moves of note in and around the biotech and pharma industries.

“Our team is excited to welcome Filip on board as we continue to identify disease-causing protein targets that may be amenable to molecular-glue-based degradation,” said Markus Warmuth, CEO of Monte Rosa Therapeutics. “We are looking forward to continuing to advance our programs toward the clinic with Filip’s leadership and expertise.”

Access options

Subscribe to Journal

Get full journal access for 1 year


only $4.92 per issue

All prices are NET prices.

VAT will be added later in the checkout.

Tax calculation will be finalised during checkout.

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

About this article

Verify currency and authenticity via CrossMark

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *